- Home
- IONS vs RVMD Comparison
IONS vs RVMD Comparison
Compare IONS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- RVMD
- Stock Information
- Founded
- IONS 1989
- RVMD 2014
- Country
- IONS United States
- RVMD United States
- Employees
- IONS N/A
- RVMD N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IONS Health Care
- RVMD Health Care
- Exchange
- IONS Nasdaq
- RVMD Nasdaq
- Market Cap
- IONS 6.9B
- RVMD 7.5B
- IPO Year
- IONS 1991
- RVMD 2020
- Fundamental
- Price
- IONS $43.78
- RVMD $36.32
- Analyst Decision
- IONS Buy
- RVMD Strong Buy
- Analyst Count
- IONS 14
- RVMD 12
- Target Price
- IONS $58.43
- RVMD $69.42
- AVG Volume (30 Days)
- IONS 2.0M
- RVMD 1.8M
- Earning Date
- IONS 07-30-2025
- RVMD 08-06-2025
- Dividend Yield
- IONS N/A
- RVMD N/A
- EPS Growth
- IONS N/A
- RVMD N/A
- EPS
- IONS N/A
- RVMD N/A
- Revenue
- IONS $944,050,000.00
- RVMD N/A
- Revenue This Year
- IONS $9.21
- RVMD N/A
- Revenue Next Year
- IONS $14.35
- RVMD $234.26
- P/E Ratio
- IONS N/A
- RVMD N/A
- Revenue Growth
- IONS 16.05
- RVMD N/A
- 52 Week Low
- IONS $23.95
- RVMD $29.17
- 52 Week High
- IONS $50.43
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- IONS 60.61
- RVMD 46.32
- Support Level
- IONS $40.37
- RVMD $34.14
- Resistance Level
- IONS $41.93
- RVMD $38.60
- Average True Range (ATR)
- IONS 1.42
- RVMD 1.39
- MACD
- IONS -0.03
- RVMD -0.02
- Stochastic Oscillator
- IONS 66.61
- RVMD 50.43
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.